BANK VONTOBEL/CALL/MODERNA/145/0.1/20.12.24 | Market Closed - Euronext Paris 17:30:00 31/05/2024 BST | ||
| 2.24 EUR | -12.84% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 2.42 | -5.84% |
| 30/05/24 | 2.57 | +5.33% |
| 29/05/24 | 2.44 | -9.63% |
| 28/05/24 | 2.7 | -30.41% |
| 27/05/24 | 3.88 | -3.72% |
Real-time Euronext Paris
Last update May 31, 2024 at 05:30 pm
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| XZ45V | |
| ISIN | DE000VD5DKK0 |
| Date issued | 06/05/2024 |
| Strike | 145 $ |
| Maturity | 20/12/2024 (201 Days) |
| Parity | 10 : 1 |
| Emission price | 1.34 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.11 € |
|---|---|
| Lowest since issue | 1.075 € |
| Spread | 0.02 € |
| Spread % | 0.88% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
142.6
USD
Average target price
139.9
USD
Spread / Average Target
-1.83%
- Stock Market
- Warrants
- XZ45V Warrant
